{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:23:02Z","timestamp":1790774582631,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.xphs.2017.06.017","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T19:16:05Z","timestamp":1498677365000},"page":"3230-3241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"title":["A Formulation Development Approach to Identify and Select Stable Ultra\u2013High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities"],"prefix":"10.1016","volume":"106","author":[{"given":"Neal","family":"Whitaker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha E.","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineet","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Russell","family":"Middaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta B.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Volkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.xphs.2017.06.017_bib1","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/07853890802698842","article-title":"Challenges in monoclonal antibody-based therapies","volume":"41","author":"Samaranayake","year":"2009","journal-title":"Ann Med"},{"issue":"4","key":"10.1016\/j.xphs.2017.06.017_bib2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s13238-010-0052-8","article-title":"Monoclonal antibodies\u2014a proven and rapidly expanding therapeutic modality for human diseases","volume":"1","author":"An","year":"2010","journal-title":"Protein Cell"},{"issue":"12","key":"10.1016\/j.xphs.2017.06.017_bib3","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.humimm.2010.09.007","article-title":"The state of antibody therapy","volume":"71","author":"Elbakri","year":"2010","journal-title":"Hum Immunol"},{"issue":"6","key":"10.1016\/j.xphs.2017.06.017_bib4","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/jps.20079","article-title":"Challenges in the development of high protein concentration formulations","volume":"93","author":"Shire","year":"2004","journal-title":"J\u00a0Pharm Sci"},{"issue":"13","key":"10.1016\/j.xphs.2017.06.017_bib5","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.addr.2011.09.008","article-title":"Viscosity of concentrated therapeutic protein compositions","volume":"63","author":"Jezek","year":"2011","journal-title":"Adv Drug Deliver Rev"},{"issue":"12","key":"10.1016\/j.xphs.2017.06.017_bib6","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/bit.260211208","article-title":"Action of shear on enzymes: studies with alcohol dehydrogenase","volume":"21","author":"Thomas","year":"1979","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.xphs.2017.06.017_bib7","series-title":"Safety of Biologics Therapy","first-page":"141","article-title":"Other approved therapeutic monoclonal antibodies","author":"Baldo","year":"2016"},{"issue":"1","key":"10.1016\/j.xphs.2017.06.017_bib8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1021\/mp500485w","article-title":"Highly viscous antibody solutions are a consequence of network formation caused by domain-domain electrostatic complementarities: insights from coarse-grained simulations","volume":"12","author":"Buck","year":"2015","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2017.06.017_bib9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/19420862.2015.1029217","article-title":"Hydrogen exchange mass spectrometry reveals protein interfaces and distant dynamic coupling effects during the reversible self-association of an IgG1 monoclonal antibody","volume":"7","author":"Arora","year":"2015","journal-title":"MAbs"},{"issue":"4","key":"10.1016\/j.xphs.2017.06.017_bib10","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/jps.24326","article-title":"Opalescence in monoclonal antibody solutions and its correlation with intermolecular interactions in dilute and concentrated solutions","volume":"104","author":"Raut","year":"2015","journal-title":"J\u00a0Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2017.06.017_bib11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/jps.24237","article-title":"Mechanism of reversible self-association of a monoclonal antibody: role of electrostatic and hydrophobic interactions","volume":"104","author":"Esfandiary","year":"2015","journal-title":"J\u00a0Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2017.06.017_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bpj.2012.04.047","article-title":"Weak interactions govern the viscosity of concentrated antibody solutions: high-throughput analysis using the diffusion interaction parameter","volume":"103","author":"Connolly","year":"2012","journal-title":"Biophys J"},{"issue":"9","key":"10.1016\/j.xphs.2017.06.017_bib13","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1007\/s11095-014-1352-0","article-title":"Dipole-dipole interaction in antibody solutions: correlation with viscosity behavior at high concentration","volume":"31","author":"Singh","year":"2014","journal-title":"Pharm Res"},{"issue":"8","key":"10.1016\/j.xphs.2017.06.017_bib14","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1080\/19420862.2016.1222342","article-title":"Charge-mediated Fab-Fc interactions in an IgG1 antibody induce reversible self-association, cluster formation, and elevated viscosity","volume":"8","author":"Arora","year":"2016","journal-title":"MAbs"},{"issue":"10","key":"10.1016\/j.xphs.2017.06.017_bib15","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/protein\/gzs047","article-title":"Mechanisms of self-association of a human monoclonal antibody CNTO607","volume":"25","author":"Bethea","year":"2012","journal-title":"Protein Eng Des Sel"},{"issue":"10","key":"10.1016\/j.xphs.2017.06.017_bib16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/protein\/gzv045","article-title":"Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy","volume":"28","author":"Wu","year":"2015","journal-title":"Protein Eng Des Sel"},{"issue":"10","key":"10.1016\/j.xphs.2017.06.017_bib17","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1002\/jps.21322","article-title":"Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity","volume":"97","author":"Kanai","year":"2008","journal-title":"J\u00a0Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2017.06.017_bib18","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/jps.20347","article-title":"Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution","volume":"94","author":"Liu","year":"2005","journal-title":"J\u00a0Pharm Sci"},{"issue":"12","key":"10.1016\/j.xphs.2017.06.017_bib19","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1021\/acs.molpharmaceut.5b00643","article-title":"Viscosity-lowering effect of amino acids and salts on highly concentrated solutions of two IgG1 monoclonal antibodies","volume":"12","author":"Wang","year":"2015","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2017.06.017_bib20","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/bit.22983","article-title":"Hydrophobic salts markedly diminish viscosity of concentrated protein solutions","volume":"108","author":"Du","year":"2011","journal-title":"Biotechnol Bioeng"},{"issue":"12","key":"10.1016\/j.xphs.2017.06.017_bib21","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1002\/jps.24630","article-title":"Modulation of the hydration water around monoclonal antibodies on addition of excipients detected by Terahertz time-domain spectroscopy","volume":"104","author":"Wallace","year":"2015","journal-title":"J\u00a0Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2017.06.017_bib22","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1021\/mp5000218","article-title":"Specific decrease in solution viscosity of antibodies by arginine for therapeutic formulations","volume":"11","author":"Inoue","year":"2014","journal-title":"Mol Pharm"},{"issue":"11","key":"10.1016\/j.xphs.2017.06.017_bib23","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1007\/s11095-012-0802-9","article-title":"Structure-activity relationship for hydrophobic salts as viscosity-lowering excipients for concentrated solutions of monoclonal antibodies","volume":"29","author":"Guo","year":"2012","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2017.06.017_bib24","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/jps.23453","article-title":"Polar solvents decrease the viscosity of high concentration IgG1 solutions through hydrophobic solvation and interaction: formulation and biocompatibility considerations","volume":"102","author":"Kamerzell","year":"2013","journal-title":"J\u00a0Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2017.06.017_bib25","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1002\/jps.22034","article-title":"Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody","volume":"99","author":"Bond","year":"2010","journal-title":"J\u00a0Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2017.06.017_bib26","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1002\/jps.23224","article-title":"Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags","volume":"101","author":"Kumru","year":"2012","journal-title":"J\u00a0Pharm Sci"},{"issue":"7","key":"10.1016\/j.xphs.2017.06.017_bib27","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.xphs.2016.03.044","article-title":"Factors governing the accuracy of subvisible particle counting methods","volume":"105","author":"Rios Quiroz","year":"2016","journal-title":"J\u00a0Pharm Sci"},{"issue":"13","key":"10.1016\/j.xphs.2017.06.017_bib29","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.addr.2011.07.006","article-title":"Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development","volume":"63","author":"Kamerzell","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2017.06.017_bib30","first-page":"26","article-title":"Integrated solutions for the delivery of high-volume biologics","volume":"51","author":"Reynolds","year":"2014","journal-title":"ONdrugDelivery"},{"issue":"1","key":"10.1016\/j.xphs.2017.06.017_bib31","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/jps.21797","article-title":"Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation","volume":"99","author":"Salinas","year":"2010","journal-title":"J\u00a0Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2017.06.017_bib32","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1002\/jps.23187","article-title":"Excipients differentially influence the conformational stability and pretransition dynamics of two IgG1 monoclonal antibodies","volume":"101","author":"Thakkar","year":"2012","journal-title":"J\u00a0Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2017.06.017_bib33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11095-015-1772-5","article-title":"Viscosity analysis of dual variable domain immunoglobulin protein solutions: role of size, electroviscous effect and protein-protein interactions","volume":"33","author":"Raut","year":"2016","journal-title":"Pharm Res"},{"issue":"26","key":"10.1016\/j.xphs.2017.06.017_bib34","doi-asserted-by":"crossref","first-page":"6665","DOI":"10.1021\/jm701032y","article-title":"Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book database","volume":"50","author":"Paulekuhn","year":"2007","journal-title":"J\u00a0Med Chem"},{"issue":"6","key":"10.1016\/j.xphs.2017.06.017_bib35","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1080\/19420862.2016.1189048","article-title":"A\u00a0comparison of biophysical characterization techniques in predicting monoclonal antibody stability","volume":"8","author":"Thiagarajan","year":"2016","journal-title":"MAbs"},{"issue":"2","key":"10.1016\/j.xphs.2017.06.017_bib36","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1021\/j150536a020","article-title":"The viscosity of aqueous solutions of bovine serum albumin between pH 4.3 and 10.5","volume":"60","author":"Tanford","year":"1956","journal-title":"J\u00a0Phys Chem-us"},{"issue":"8","key":"10.1016\/j.xphs.2017.06.017_bib37","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s11095-011-0424-7","article-title":"Viscosity analysis of high concentration bovine serum albumin aqueous solutions","volume":"28","author":"Yadav","year":"2011","journal-title":"Pharm Res"},{"issue":"31","key":"10.1016\/j.xphs.2017.06.017_bib38","doi-asserted-by":"crossref","first-page":"9310","DOI":"10.1021\/jp302748k","article-title":"Hard quasispherical particle models for the viscosity of solutions of protein mixtures","volume":"116","author":"Minton","year":"2012","journal-title":"J\u00a0Phys Chem B"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2017.06.017_bib39","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijpharm.2014.06.053","article-title":"The effect of arginine glutamate on the stability of monoclonal antibodies in solution","volume":"473","author":"Kheddo","year":"2014","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2017.06.017_bib40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11095-016-2055-5","article-title":"Contrasting the influence of cationic amino acids on the viscosity and stability of a highly concentrated monoclonal antibody","volume":"34","author":"Dear","year":"2017","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.xphs.2017.06.017_bib41","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.febslet.2014.01.051","article-title":"Competing aggregation pathways for monoclonal antibodies","volume":"588","author":"Wu","year":"2014","journal-title":"FEBS Lett"},{"issue":"4","key":"10.1016\/j.xphs.2017.06.017_bib42","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/jps.22384","article-title":"Screening of monoclonal antibody formulations based on high-throughput thermostability and viscosity measurements: design of experiment and statistical analysis","volume":"100","author":"He","year":"2011","journal-title":"J\u00a0Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2017.06.017_bib43","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1517\/17425247.2014.876989","article-title":"Emerging methods for identifying monoclonal antibodies with low propensity to self-associate during the early discovery process","volume":"11","author":"Tessier","year":"2014","journal-title":"Expert Opin Drug Deliv"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354917304860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354917304860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T21:34:42Z","timestamp":1575322482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354917304860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0022354917304860"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2017.06.017","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Formulation Development Approach to Identify and Select Stable Ultra\u2013High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2017.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}